Free Trial
→ No. You’re not imagining it… (From Porter & Company) (Ad)tc pixel Free HLS Stock Alerts

HLS Therapeutics (HLS) Competitors

HLS Therapeutics logo
C$4.65 +0.01 (+0.22%)
As of 05/25/2026 04:00 PM Eastern
Compare

HLS vs. CPH, ACB, SUGR, FIRE, and EPI

Should you buy HLS Therapeutics stock or one of its competitors? MarketBeat compares HLS Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HLS Therapeutics include Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for HLS Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company Overall Sentiment
Cipher Pharmaceuticals Neutral
HLS Therapeutics Neutral

Cipher Pharmaceuticals has a beta of 0.894897, indicating that its share price is 11% less volatile than the broader market. Comparatively, HLS Therapeutics has a beta of 0.392903, indicating that its share price is 61% less volatile than the broader market.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 3.16%. HLS Therapeutics has a consensus price target of C$6.00, indicating a potential upside of 29.03%. Given HLS Therapeutics' higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to HLS Therapeutics' net margin of -18.42%. Cipher Pharmaceuticals' return on equity of 25.69% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals60.82% 25.69% 7.90%
HLS Therapeutics -18.42%-16.54%-2.89%

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 5.4% of HLS Therapeutics shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has higher earnings, but lower revenue than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$50.94M8.21C$11.41MC$1.1913.85
HLS TherapeuticsC$55.74M2.61-C$15.53M-C$0.32N/A

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 11 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

HLS Therapeutics (TSE:HLS) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

5.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Aurora Cannabis shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HLS Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.61-C$15.53M-C$0.32N/A
Aurora CannabisC$373.12M0.77-C$44.16M-C$1.50N/A

Aurora Cannabis has a net margin of -1.69% compared to HLS Therapeutics' net margin of -18.42%. Aurora Cannabis' return on equity of -1.15% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Aurora Cannabis -1.69%-1.15%-1.87%

HLS Therapeutics has a beta of 0.392903, meaning that its share price is 61% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.415152, meaning that its share price is 58% less volatile than the broader market.

HLS Therapeutics currently has a consensus target price of C$6.00, indicating a potential upside of 29.03%. Aurora Cannabis has a consensus target price of C$9.25, indicating a potential upside of 89.16%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Aurora Cannabis'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Aurora Cannabis Neutral

Summary

Aurora Cannabis beats HLS Therapeutics on 9 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to SugarBud Craft Growers?

SugarBud Craft Growers (CVE:SUGR) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

SugarBud Craft Growers has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft GrowersC$662.89M0.45C$12.12MC$1.408.86
HLS TherapeuticsC$55.74M2.61-C$15.53M-C$0.32N/A

SugarBud Craft Growers has a net margin of 2.11% compared to HLS Therapeutics' net margin of -18.42%. SugarBud Craft Growers' return on equity of 10.07% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SugarBud Craft Growers2.11% 10.07% 5.13%
HLS Therapeutics -18.42%-16.54%-2.89%

In the previous week, SugarBud Craft Growers' average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company Overall Sentiment
SugarBud Craft Growers Neutral
HLS Therapeutics Neutral

SugarBud Craft Growers has a beta of 2.768948, suggesting that its stock price is 177% more volatile than the broader market. Comparatively, HLS Therapeutics has a beta of 0.392903, suggesting that its stock price is 61% less volatile than the broader market.

0.4% of SugarBud Craft Growers shares are held by institutional investors. Comparatively, 5.4% of HLS Therapeutics shares are held by institutional investors. 30.2% of SugarBud Craft Growers shares are held by insiders. Comparatively, 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

SugarBud Craft Growers beats HLS Therapeutics on 9 of the 11 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Supreme Cannabis Neutral

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Supreme Cannabis N/A N/A N/A

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.61-C$15.53M-C$0.32N/A
Supreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/A

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Supreme Cannabis beats HLS Therapeutics on 5 of the 9 factors compared between the two stocks.

How does HLS Therapeutics compare to ESSA Pharma?

ESSA Pharma (CVE:EPI) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, ESSA Pharma's average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company Overall Sentiment
ESSA Pharma Neutral
HLS Therapeutics Neutral

ESSA Pharma has higher earnings, but lower revenue than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/AN/A-C$0.99N/A
HLS TherapeuticsC$55.74M2.61-C$15.53M-C$0.32N/A

ESSA Pharma has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. ESSA Pharma's return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ESSA PharmaN/A N/A N/A
HLS Therapeutics -18.42%-16.54%-2.89%

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ESSA Pharma and HLS Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HLS vs. The Competition

Export
MetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$145.43MC$2.22BC$6.46BC$12.16B
Dividend Yield4.30%2.95%2.76%6.20%
P/E Ratio-14.535.1621.2237.64
Price / Sales2.611,770.59553.9211.68
Price / Cash15.2210.1843.4982.29
Price / Book2.4810.6110.374.50
Net Income-C$15.53MC$20.70BC$3.57BC$299.09M
7 Day Performance2.65%8.23%6.40%2.48%
1 Month Performance1.31%3.77%3.52%1.47%
1 Year Performance-7.00%22.84%34.02%53.55%

HLS Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
N/AC$4.65
+0.2%		C$6.00
+29.0%		-0.6%C$145.43MC$55.74MN/A91
CPH
Cipher Pharmaceuticals
0.5544 of 5 stars		C$16.99
+0.4%		C$17.00
+0.1%		+32.7%C$431.39MC$50.94M14.285
ACB
Aurora Cannabis
1.5872 of 5 stars		C$4.91
+2.9%		C$9.25
+88.4%		-35.1%C$290.31MC$373.12MN/A1,073
SUGR
SugarBud Craft Growers
N/AC$10.80
flat		N/A+1.2%C$259.95MC$668.94M6.4344
FIRE
Supreme Cannabis
N/AN/AN/AN/AC$259.40MC$53.29MN/A400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel